The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

In the Pipeline: Treating HIV With a Patch Instead of Pills

October 28, 2011

Preliminary research suggests that HIV drugs could be delivered via a transdermal patch. The developers, led by Anthony Ham, director of formulations at the pharmaceutical research company ImQuest BioSciences, presented a study at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which was held in Washington, D.C., from Oct. 23 through 27.

Ham and his colleagues tested the effectiveness of administering IQP-0410, an HIV drug that is currently under development, via a skin patch. They found that the patch delivered more than 96 percent of the drug over a week-long period. While the method has yet to be tested in animals and humans, this is promising news, especially for those with adherence difficulties.

HealthDay reported:

Patients with HIV, the virus that causes AIDS, don't need to cope with the complicated regimens of earlier years that required them to take multiple pills at different times throughout the day. Now, about 70 percent of newly treated patients in the United States take a single pill a day, while patients in other parts of the world may take one pill twice a day, said Rowena Johnston, director of research with the Foundation for AIDS Research.

"Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence," Johnston noted. Research has shown that many patients, if not most, don't take their pills all the time.

"The huge potential advantage of a patch, depending on how long it secretes the right level of drug, is the ability to maintain the right level of the drug without the fluctuations observed when adherence to pills is less than perfect," Johnston said.

A patch could also be an effective way to provide medication that prevents people from getting HIV in the first place, she said.

Moreover, compared to pills and needles, the low-cost patch could be more affordable and accessible, which could thereby drive down the ever-growing cost of current HIV treatment -- perhaps even impacting our ADAP crisis. Only time will tell.

Read the AAPS press release.

Warren Tong is the research editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2011 The HealthCentral Network, Inc. All rights reserved.

This article was provided by TheBody.
See Also
More on HIV Medications
Drugs in Development: Other New Drugs

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.